GleamWall
中文EN

HIND Vyome Holdings, Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1427570 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-55.6%
TTM net income YoY59.8%
TTM EPS YoY100.2%
Revenue 3-yr CAGR-75.0%
Net income 3-yr CAGR—

Margins

Gross margin50.4%
Operating margin-2,853.6%
Net margin-2,455.6%
FCF margin—
EBITDA margin-2,846.7%

Returns

ROE-95.7%
ROA-48.0%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets24.0%
Debt / equity0.00x
Current ratio3.68x
Interest coverage-229.34x

Cash quality & payout

Operating cash flow / net income1.18x
Accruals ratio8.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$57,998$26,955$31,591$36,551$34,627$49,954$198,581$61,428
Cost of revenue$31,196$15,297$14,946$14,485$16,577$25,719$44,162-$1,333
Gross profit$26,802$11,658$16,645$22,066$18,050$24,235$154,419$62,761
R&D expense$409,831$506,723$666,405$378,252$39,677$80,061$90,268$67,527
SG&A expense$635,410$364,891$477,575$996,200$844,344$265,395$259,626$247,376
Operating income-$1.02M-$862,566-$1.13M-$1.36M-$8.57M-$324,189-$198,998-$256,006
Interest expense$2,935$3,325$2,845$9,944$25,604$56,139$54,954$52,775
Pretax income—————-$2.62M$1.48M-$1.76M
Income tax—————$8,000$7,000$5,000
Net income-$885,408-$685,556-$962,910-$1.23M-$8.43M-$308,760-$293,974-$306,557
EBITDA-$1.02M-$859,956-$1.13M-$1.35M-$8.57M-$321,221-$195,475-$252,142
EPS (basic)-0.13-0.10-0.15—-3.06-799.90-761.59—
EPS (diluted)-0.13-0.10-0.15—-3.06-799.90-761.59—
Weighted avg. shares (diluted)——6.69M—2.76M1.17M386—
Balance sheet
Cash & equivalents$6.96M$7.89M$8.80M$4.98M$5.71M$383,386$58,370$101,904
Receivables$9,096$2,181$309$325$23,001$1.40M$700,000$2,294
Inventory—————$2.55M$2.53M$2.46M
Current assets$7.60M$8.15M$9.16M$5.44M$6.04M$8.86M$6.29M$302,046
PP&E, net$41,254$42,416$44,429$46,393$50,168$30,000$34,000$59,179
Intangibles$314,191$314,191$314,191$314,191$314,191——$314,191
Total assets$8.61M$9.18M$10.19M$6.50M$7.05M$9.03M$1.44M$1.38M
Current liabilities$2.07M$1.86M$2.14M$2.74M$3.12M$3.20M$4.12M$5.74M
Short-term debt———————$811,000
Total liabilities$2.07M$1.86M$2.14M$2.74M$3.13M$3.20M$5.25M$5.77M
Shareholders' equity$5.33M$6.05M$6.74M$2.44M$2.53M$5.83M$1.23M-$4.39M
Shares outstanding7.02M7.02M7.02M5.92M—2.62M133,0810
Cash flow statement
Operating cash flow-$627,577-$903,712-$1.44M-$1.48M-$1.72M-$306,251-$203,533-$2,968
Investing cash flow———————$1,466
Financing cash flow-$289,075-$3,000$5.29M$764,020$7.06M$631,253$160,000$53,466
Depreciation & amortization$2,702$2,610$2,605$2,688$2,806$2,968$3,523$3,864
Stock-based compensation$175,804$11,051$5,696$3,019$574,109$12,000$0$15,000

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.